U.S. Drug Makers Continue To Face Hurdles Getting Chinese, Indian APIs

China might be over the peak of its coronavirus curve, but the steep decline in Chinese exports of active pharmaceutical ingredients to the United States and other countries likely will continue, a Congressional Research Service study finds . CRS says complications in ocean freight and political calculations may continue to make it difficult for U.S. generic drug companies to obtain APIs from China and in turn India, which could lead to increased drug prices for Americans. J.P Duffy, an international...